en · de · es · fr · pt
cjc-1295-notes.peptides6908.com › Topic › Background And Molecular Features — Beginner to Advanced

Background And Molecular Features — Beginner to Advanced

By Editorial Desk · published 2026-02-16 · last reviewed 2026-03-04 · Topic

The short version of drug affinity complex fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-03-04 and is reviewed periodically as new material appears.

Background and Molecular Features

The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.

CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.

Receptor Action and Pharmacokinetics

The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.

Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.

CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.

Cjc-1295 at a glance

PropertyValueNotes
ClassSynthetic peptideGHRH receptor agonist
Sequence length29 amino acidsDerived from human GHRH
Molecular weightAbout 3368 Da without linkerAlbumin-binding form is heavier
AppearanceWhite to off-white lyophilized powderCommon form for research reference material
Typical storage-20 °C or below, desiccatedProtect powder from light and moisture

Background and Naming Conventions

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.

The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.

Related pages on this site

Background and Receptor Mechanism

Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.

At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.

CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.

Persistence, Stability and Measurement

Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.

The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.

Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.

Reference notes

French president Emmanuel Macron initially expressed joy, declaring on social media that "Maduro is a dictator, and his departure is good news for Venezuelans. He confiscated the freedom of his people and stole the 2024 elections." However, days later he nuanced his message, saying that the method employed by the Americans "does not have the support or approval" of France. United Kingdom prime minister Keir Starmer said that he was happy for the fall of Maduro, and he would wait to know the facts before commenting further. José Antonio Kast, the president-elect of Chile, stated that Maduro was not the legitimate president of Venezuela, had "destabilized Latin America", called his capture "great news", and remarked that work remained and the "governments of Latin America must ensure that the entire apparatus of the regime relinquishes power and is held accountable". Spanish prime minister Pedro Sánchez urged de-escalation, stating that "[i]nternational law and the principles of the U.N. Charter must be respected"; this was echoed by European Union (EU) foreign policy chief and European Commission vice-president Kaja Kallas. The governments of Brazil, Colombia, Mexico, Spain, Uruguay, and the outgoing administration in Chile issued a joint statement rejecting the US action and expressed their concern saying that it could "constitute an extremely dangerous precedent for peace and regional security and endanger the civilian population".

Methanediamine is the simplest geminal diamine. Its chemical formula is CH2(NH2)2, and its structure consists of two amino groups on a central carbon atom. Although methanediamine only exists transiently in solution, its hydrochloride salt has been used in chemical synthesis since 1914. The hydrochloride is useful for the synthesis of primary amides from amino acids.

== Mechanical and thixotropic agents == Fumed silica and similar products form stiff microscopic chains or fibers which interlock or agglomerate into a mass, holding the associated liquid by surface tension, but which can separate or slide when sufficient force is applied. This causes the thixotropic or shear-thinning property (also frequently exhibited by gels), where the viscosity is non-Newtonian and becomes lower as the shearing force or time increases; their usefulness is primarily that the resulting increase in viscosity is large compared to the quantity of silica added. Fumed silica is generally accepted as safe as a food additive and is frequently used in cosmetics. Additives such as precipitated silica, fine talc, or chalk also meet the definition of thickening agent in that they increase viscosity and body while not affecting the target property of a mixture.

Due to limited data however, more research on potential tolerance and withdrawal effects of moderate doses of doxepin is needed. At these doses of doxepin, dry mouth, an anticholinergic effect, was common (71%), and other side effects such as headache (25%), increased appetite (21%), and dizziness (21%) were also frequently observed, although these adverse effects were notably not significantly more frequent than with placebo in the study in question. In any case, taken together, higher doses of doxepin than very low doses are associated with an increased rate of side effects as well as apparent loss of hypnotic effectiveness with chronic treatment. Doxepin at a dose of 25 mg/day for 3 weeks has been found to decrease cortisol levels by 16% in adults with chronic insomnia and to increase melatonin production by 26% in healthy volunteers. In individuals with neuroendocrine dysregulation in the form of nocturnal melatonin deficiency presumably due to chronic insomnia, very-low-dose doxepin was found to restore melatonin levels to near-normal values after 3 weeks of treatment. These findings suggest that normalization of the hypothalamic–pituitary–adrenal axis and the circadian sleep–wake cycle may be involved in the beneficial effects of doxepin on sleep and insomnia.

Sources: en.wikipedia.org

Notes from published material

Later, in the 1970s, there was a high possibility of conflict between Chile and Peru, between Chile and Argentina, and between Peru and Ecuador, which were feared that they would become entangled in a war on a continental scale. During the government of the dictator Augusto Pinochet, there were tensions between the two countries, due not only to the geopolitical rivalry in the South Pacific and the nationalist sentiments of both countries, but also due to certain ideological differences between the right-wing Pinochet regime and the leftist regime of the Peruvian dictator, Juan Velasco Alvarado, in the framework of the Cold War, to whom the Chilean military leadership attributed a determined military will to recover the provinces of Arica and Tarapacá before the centenary of the War of the Pacific, even before the Coup de State against Allende. There is a record of at least 2 occasions in which Pinochet came to seriously consider the idea of starting a preventive war against Peru. In 1974, Pinochet summoned the General Staff of the National Defense of Chile to analyze the possibility of attempting a massive military attack on Peru (preventing the Peruvians from attacking first), however, he only obtained the support of the Army, but not that of the Navy or Air Force, whose officers feared the Peruvian military superiority of back then.

=== Signs and symptoms === Patients with periwound issues may experience burning, itching, tenderness, and pain. Visible and measurable signs include rash, erythema, discoloration, changes in skin texture and temperature.

Ultraviolet (UV) light induces the formation of covalent linkages on DNA and thereby prevents microbes from reproducing. Without reproduction, the microbes become far less dangerous. Germicidal UV-C light in the short wavelength range of 100–280 nm acts on thymine, one of the four base nucleotides in DNA. When a germicidal UV photon is absorbed by a thymine molecule that is adjacent to another thymine within the DNA strand, a covalent bond or dimer between the molecules is created. This thymine dimer prevents enzymes from "reading" the DNA and copying it, thus neutering the microbe. Prolonged exposure to ionizing radiation can cause single and double-stranded breaks in DNA, oxidation of membrane lipids, and denaturation of proteins, all of which are toxic to cells. Still, there are limits to this technology. Water turbidity (i.e., the amount of suspended & colloidal solids contained in the water to be treated) must be low, such that the water is clear, for UV purification to work well - thus a pre-filter step might be necessary. A concern with UV portable water purification is that some pathogens are hundreds of times less sensitive to UV light than others. Protozoan cysts were once believed to be among the least sensitive, however recent studies have proved otherwise, demonstrating that both Cryptosporidium and Giardia are deactivated by a UV dose of just 6 mJ/cm2 However, EPA regulations and other studies show that it is viruses that are the limiting factor of UV treatment, requiring a 10-30 times greater dose of UV light than Giardia or Cryptosporidium.

Sources: en.wikipedia.org

Frequently asked questions

What is the difference between CJC-1295 and natural GHRH?

Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.

Why does one name cover two different peptides?

The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.

Is CJC-1295 a steroid or a natural hormone?

It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.

How does CJC-1295 raise growth hormone levels?

It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.

Network